Monday, 12 January 2015 07:00 AM
MINNEAPOLIS, MN / ACCESSWIRE / January 12th, 2015 / PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce the continued expansion of the patent portfolio of its merging partner Gel-Del Technologies, Inc.
With the recent mucoadhesive drug delivery patent allowance by the Canadian Intellectual Property Office, Gel-Del's intellectual property portfolio has grown to seventeen allowed patents, seven of which are US patents. Gel-Del has an additional nineteen patent applications pending in the US and strategic foreign countries.
The scope of coverage for this mucosal drug delivery intellectual property includes a broad range of therapeutic products and treatments for pets, people and livestock. A key technology covered in this patent is the Gel-Del mucosal pharmaceutical delivery system, OraPatch(TM), which is a slowly degradable protein wafer-disc that strongly attaches to and assimilates with the mouth's mucosal membrane. OraPatch provides a nearly undetectable and secure mucosal attachment for the controlled release period so its contents can circulate within the mouth longer as it degrades away to dissolved material. In addition, OraPatch can be fabricated for transmucosal delivery, eliminating gastrointestinal tract (GI) issues that can be caused by traditional oral pharmaceutical delivery, enhancing bioavailability and reducing the amount of pharmacologically active agent needed.
"We now possess the intellectual property to protect our proprietary oral delivery products and their veterinary and human treatment applications," commented Gel-Del's CEO, Dr. David B. Masters. "This degradable mucosal attachment technology provides greater residency time to improve therapeutic effectiveness for a broad range of products, including delivery of nutraceuticals, vitamins, mouth care agents, and a wide range of pharmaceuticals. We are pleased to have patent protection for our transmucosal delivery system that will initially target the dental hygiene, pain and incontinence markets in the veterinary space."
The US Patent Office has issued a corresponding patent number 8,529,939 titled "Mucoadhesive Drug Delivery Devices and Methods of Making and Using Thereof." In addition, both the European and Australian Patent Offices have also allowed a corresponding patent.
"We are very excited about the breadth and scope of Gel-Del's expansive intellectual property portfolio" PetVivo CEO John Lai commented, "Gel-Del's novel materials and unique manufacturing processes give us a competitive advantage in providing effective therapeutics for both pets and people in large underserved markets."
Gel-Del diligently protects its proprietary technologies, including the composition of raw elements used to produce its formulations, the fabricated biomaterials and their application in end products and devices. To maximize the strength and value of Gel-Del's intellectual property the claims generally cover the commercial devices/therapeutics, the manufacturing methods and the methods of use of Gel-Del's proprietary technology.
PetVivo Holdings and Gel-Del Technologies previously announced that they entered into a definitive stock exchange agreement that is scheduled to close by the end of Q1 2015.
About Gel-Del Technologies, Inc
Gel-Del Technologies (www.gel-del.com) is a biomaterial and medical device manufacturing company based in St. Paul, Minnesota. The company successfully completed a pivotal clinical trial using their novel thermoplastic biomaterial as an injected dermal filler for human facial contour applications (clinicaltrials.gov NCT00414544).
Gel-Del's core competencies include the development and manufacturing of medical devices containing its proprietary biomaterials with or without pharmaceuticals. Using its patented thermoplastic and/or compression manufacturing technologies, purified proteins and carbohydrates are accurately self-assembled and fabricated into cell supporting and tissue compatible biomaterial scaffolds. These "made from scratch" biological scaffolds have the hydrophilic biomimetic structure of the body's non-cellular tissue allowing in vivo biochemical interaction, cellular integration, neovascularization, tissue repair, and regeneration as a temporary or permanent implant.
These non-soluble biomaterials are produced using a patented and reproducible-scalable process that is FDA-validated for human clinical trial production. The inherent properties of these biomaterials allow thermoplastic or liquid coating techniques to manufacture implantable devices of all shapes and sizes, including particles for injection and as drug delivery devices at any pharmaceutical dose.
About PetVivo, Inc
PetVivo, Inc. is a wholly owned subsidiary of PetVivo Holdings, Inc. (OTCPINK:PETV) based in Minneapolis, Minnesota. PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and other therapeutics for pets.
PetVivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
Forward-Looking Statements
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Contact:
John Lai
Chief Executive Officer
PetVivo Holdings, Inc.
[email protected]
612-296-7305
SOURCE: PetVivo Holdings, Inc.